Enliven Therapeutics raises $400M as Jazz's Zepzelca misses confirmatory trial

Enliven Therapeutics, a biotech based in Burlingame, California, announced that it priced a public offering of its common stock that raised about $400 million.

The capital raise follows the company's recent data disclosures and is intended to fund ongoing development programs and corporate initiatives.

In separate news, Jazz Pharmaceuticals reported that its oncology drug Zepzelca did not meet the primary endpoints in a confirmatory study, marking a setback for the product's regulatory prospects.

The briefing also noted brief updates concerning Caribou, Adial, and the Beneluxa Initiative, though no detailed information was provided.